Neuro3d initiates Phase I trials for depression drug
Neuro3d, a biopharmaceutical company focused on drug discovery and development for psychiatric disorders, has initiated Phase I clinical trials with ND7001, a new type of antidepressant drug with anxiolytic activity.
Neuro3d, a biopharmaceutical company focused on drug discovery and development for psychiatric disorders, has initiated Phase I clinical trials with ND7001, a new type of antidepressant drug with anxiolytic activity.
ND7001, which acts on a new target that has never been associated with depression or anxiety, is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.
'Due to its entirely novel mechanism of action, ND7001 possesses certain attributes that, if translated and confirmed in humans, could result in a completely new option for patients allowing the simultaneous treatment of depression and anxiety,' said Charles Woler, ceo of Neuro3d.
Initially, a double-blind, placebo-controlled, single dose-escalation study will be conducted to investigate safety, tolerability and pharmacokinetics. Thereafter, a multiple-dose study will be conducted to provide evidence of CNS effects and active dose range.